 |
1) The rationale of acid suppression in the treatment of acid-related disease. Mohamed, AH; Hunt, RH. Aliment. Pharmacol. Ther. 8(suppl.1) 3-10; 1994. |
| |
2) Pantoprazole vs. ranitidine in treatment of acute duodenal ulcer - German multicenter study. Schepp, W; Classen, M. Gastroenterology, 104(4), Part 2: A186; 1993. |
| |
3) Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Hotz, J; Plein, K; et al. Scand J Gastroenterol, 30, 111-115; 1995. |
| |
4) Review article : the continuing development of proton pump inhibitors with particular reference to pantoprazole. Huber, R; Kohl, B; et al. Aliment. Pharmacol. Ther. 9:363-378; 1995. |
| |
5) Comparison of the 24h intragastric pH profiles following single and repeated oral intake of pantoprazole 40mg and omeprazole 20mg in healthy male volunteers. Hartmann, M; Theiss, U; et al. Gastroenterology 104(4) Part2: A95; 1993. |
| |
6) Pantoprazole - A review of its pharmacological properties and therapeutic use in acid-related disorders. Fitton, A; Wiseman, L. Drugs 51(3): 460-482; 1996. |
| |
7) Clinical's Manual on Drug Interactions in Gastroenterology. Maton, P; Burton, M. Life Science Communications, London, 1996, 18-19. |
| |
8) Consenso nacional sobre o H. pylori e afecções associadas. Coelho, L.G.V.; Barros, C.A.S.; e cols. GED, 15(2), 53-58, 1996. |
